EIF4E3

Across TCGA pan-cancer cohorts, EIF4E3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EIF4E3 data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EIF4E3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EIF4E3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where EIF4E3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.511	0.312	<.001	60	view →
CCRCC	DFS	Median	III,IV	0.779	0.348	<.001	34	view →
LUAD	DFS	Quartile	All	0.845	0.362	<.001	15	view →
LSCC	OS	Quartile	II,III,IV	0.560	0.917	.021	12	view →
HNSC	DFS	Tertile	All	1.000	0.623	.040	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EIF4E3–PDAC (DFS)

Open the PDAC breakdown →